ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 320

Evaluation of Anti-Citrullinated Type II Collagen and Anti-Citrullinated Vimentin Antibodies in Patients with Juvenile Idiopathic Arthritis

Brooke Gilliam1, Anil K. Chauhan2 and Terry L. Moore3, 1IM-Rheumatology, Saint Louis University, St. Louis, MO, 2Rheumatology, Saint Louis University, St. Louis, MO, 3Rheumatology/Immunology, Saint Louis University, St. Louis, MO

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Anti-CCP antibodies and juvenile idiopathic arthritis (JIA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Pathogenesis and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Several studies have identified anti-cyclic citrullinated peptide (CCP) antibodies as an important indicator for destructive disease in patients with juvenile idiopathic arthritis (JIA). This is of particular significance in patients with IgM rheumatoid factor (RF)-positive polyarticular JIA, which closely resembles rheumatoid arthritis (RA). While the role of anti-CCP antibodies in RA and JIA is better understood, the identity of the target proteins of this modification remains undefined. We evaluated serum from patients with JIA to investigate the presence of anti-citrullinated type II collagen (CII) and anti-citrullinated vimentin antibodies, and their association with RF and anti-CCP antibody isotypes and previously measured anti-citrullinated fibrinogen and α-enolase antibodies. Our aim was to determine the prevalence and significance of previously identified target proteins for citrullination and elucidate their role in the disease process of JIA.

Methods:

Sera were obtained from 96 patients with various JIA subtypes, 19 systemic lupus erythematous (SLE) patients, and 10 healthy children. All sera were measured for antibodies against citrullinated and native CII and vimentin (vim1-16, vim59-74) by ELISA. Results were compared to anti-CCP antibody and RF isotypes, and our previously measured anti-citrullinated fibrinogen antibodies and anti-citrullinated α-enolase antibodies, in addition to erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).

Results: 

Mean levels of all anti-citrullinated antibodies were significantly higher in JIA patients than in healthy children (p<0.05). The most commonly detected citrullinated autoantibodies were anti-citrullinated CII (33.3%) and anti-citrullinated fibrinogen antibodies (32.3%), with the least commonly detected being anti-citrullinated α-enolase antibodies (9.4%). One IgM RF-positive polyarthritis patient was positive for all tested anti-citrullinated autoantibodies. The most common combination of positivity was anti-citrullinated CII and anti-citrullinated fibrinogen antibodies in 7 patients. Twenty-two subsets of patients were identified based on their anti-citrullinated autoantibody profile, not including anti-CCP antibody isotypes. Anti-citrullinated CII antibodies correlated significantly with all other citrullinated autoantibodies (p<0.05). Anti-citrullinated vimentin 1-16 and 59-74 demonstrated strong correlation with each other, and both correlated significantly with anti-citrullinated fibrinogen and alpha-enolase antibodies (p<0.05). Anti-citrullinated vimentin 1-16 antibodies also correlated with ESR (p<0.05). When including the group of citrullinated autoantibodies in logistic regression analysis, anti-citrullinated fibrinogen remained as the only autoantibody significantly correlated with joint damage (p<0.05).

Conclusion:

This study demonstrates that multiple citrullinated epitopes can be detected in JIA patients, especially those patients with polyarticular disease. Anti-citrullinated fibrinogen antibodies remained as the single citrullinated autoantibody to correlate significantly with joint damage.


Disclosure:

B. Gilliam,
None;

A. K. Chauhan,
None;

T. L. Moore,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-anti-citrullinated-type-ii-collagen-and-anti-citrullinated-vimentin-antibodies-in-patients-with-juvenile-idiopathic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology